Streetbeat News

Analyst Ratings

DUK

Barclays analyst Eric Beaumont maintains an Overweight rating on Duke Energy (NYSE:DUK) and raises the price target from $96 to $97.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 1:14 pm

THC

Cantor Fitzgerald analyst Sarah James maintains an Overweight rating on Tenet Healthcare (NYSE:THC) and raises the price target from $76 to $94.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 1:13 pm

PGNY

Cantor Fitzgerald analyst Sarah James maintains an Overweight rating on Progyny (NASDAQ:PGNY) and raises the price target from $45 to $48.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 1:13 pm

CI

Cantor Fitzgerald analyst Sarah James has maintained a Neutral rating on Cigna Group (NYSE:CI) and raised the price target from $292 to $310.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 1:12 pm

AMED

Cantor Fitzgerald analyst Sarah James maintains a Neutral rating on Amedisys (NASDAQ:AMED) and raises the price target from $100 to $101.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 1:11 pm

ACHC

Cantor Fitzgerald analyst Joseph France has maintained a Neutral rating on Acadia Healthcare Co (NASDAQ:ACHC) and raised the price target from $83 to $85.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 1:11 pm

BMRN

Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a price target of $120.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 1:09 pm

EYPT

Cantor Fitzgerald analyst Jennifer Kim has reiterated an Overweight rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and maintained a $31 price target.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 1:08 pm

MLTX

Cantor Fitzgerald analyst Prakhar Agrawal has reiterated an Overweight rating on MoonLake (NASDAQ:MLTX) and maintained a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 1:07 pm

EVLV

Cantor Fitzgerald analyst Brett Knoblauch has reiterated an Overweight rating on Evolv Technologies (NASDAQ:EVLV) and maintained a price target of $8.6.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 1:06 pm